Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2011-08-09
2011-08-09
Ouspenski, Ilia (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Reexamination Certificate
active
07994283
ABSTRACT:
A dimeric protein comprising a first fusion protein and a second fusion protein, wherein the first fusion protein comprises a targeting domain, a leucine zipper domain, and an antigen; and wherein the second fusion protein comprises a targeting domain, a leucine zipper domain, and optionally an antigen. Nucleic acid vectors encoding proteins of the invention are provided, particularly for use in nucleic acid vaccination.
REFERENCES:
patent: WO 98/44129 (1998-10-01), None
patent: WO 01/02440 (2001-01-01), None
Black et al., Molecular Cell, 2007, 25: 309-322.
Armand et al., “Targeted Expression of HTLV-1 Envelope Proteins in Muscle by DNA Immunization of Mice,” Vaccine 18:2212-2222 (2000).
Barnhart et al., “Enhancer and Promoter Chimeras in Plasmids Designed for Intramuscular Injection: A Comparative in Vivo and in Vitro Study,” Hum. Gene Ther. 9:2545-2553 (1998).
Boyle et al., “Enhanced Responses to a DNA Vaccine Encoding a Fusion Antigen That Is Directed to Sites of Immune Induction,” Nature 392:408-411 (1998).
Chaplin et al, “Targeting Improves the Efficacy of a DNA Vaccine AgainstCorynebacterium pseudotuberculosisin Sheep,” Infection and Immunity 67:6434-6438 (1999).
Choo et al., “Vaccination of Chimpanzees Against Infection by the Hepatitis C Virus,” Proc. Natl. Acad. Sci. USA 91:1294-1298 (1994).
Deliyannis et al., “A Fusion DNA Vaccine That Targets Antigen-Presenting Cells Increases Protection From Viral Challenge,” Proc. Natl. Acad. Sci. USA 97(12):6676-6680 (2000).
Donnelly et al., “DNA Vaccines,” Annu. Rev. Immunol 15:617-648 (1997).
Fuller et al., “Enhancement of Immunodeficiency Virus-Specific Immune Responses in DNA-ImmunizedRhesus macaques,” Vaccine 15(8):924-925 (1997).
Greene et al., “Covalent Dimerization of CD28/CTLA-4 and Oligomerization of CD80/CD86 Regulate T Cell Costimulatory Interactions,” J. Biol. Chem. 271(43):26762-26771 (1996).
Habersetzer et al., “Isolation of Human Monoclonal Antibodies (HMABS) Directed At Conformational Determinants of the Hepatitis C Virus (HCV) E2 Envelope Protein,” Hepatology 24(4):381A (1996).
Hartikka et al., “AM Improved Plasmid DNA Expression Vector for Direct Injection Into Skeletal Muscle,” Hum. Gene Ther. 7:1205-1217 (1996).
Heile et al., “Evaluation of Hepatitis C Virus Glycoprotein E2 for Vaccine Design: An Endoplasmic Reticulum-Retained Recombinant Protein Is Superior to Secreted Recombinant Protein and DNA-Based Vaccine Candidates,” J. Virol. 74(15):6885-6892 (2000).
Kwissa et al., “Efficient Vaccination by Intradermal or Intramuscular Inoculation of Plasmid DNA Expressing Hepatitis B Surface Antigen Under Desmin Promoter/Enhancer Control,” Vaccine 18:2337-2344 (2000).
Leitner et al., “DNA and RNA-Based Vaccines: Principles, Progress and Prospects,” Vaccine 18:765-777 (2000).
Lew et al., “Site-Directed Immune Responses in DNA Vaccines Encoding Ligand-Antigen Fusions,” Vaccine 18:1681-1685 (2000).
Linsley et al., “T-Cell Antigen CD28 Mediates Adhesion With B Cells by Interacting With Activation Antigen B7/BB-1,” Proc. Natl. Acad. Sci. USA 87:5031-5035 (1990).
Matthias et al., “Two Pairs of Oppositely Charged Amino Acids From JUN and FOS Confer Heterodimerization to GCN4 Leucine Zipper,” The Journal of Biological Chemistry 269(23):16247-16253 (1994).
Pardoll et al., “Exposing the Immunology of Naked DNA Vaccines,” Immunity 3:165-169 (1995).
Rosa et al., “A Quantitative Test to Estimate Neutralizing Antibodies to the Hepatitis C Virus: Cytofluorimetric Assessment of Envelope Glycoprotein 2 Binding to Target Cells,” Proc. Natl. Acad. Sci. USA 93:1759-1763 (1996).
Sato et al., “Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization,” Science 273:352-354 (1996).
Schouten et al., “The C-Terminal KDEL Sequence Increases the Expression Level of a Single-Chain Antibody Designed to Be Targeted to Both the Cytosol and the Secretory Pathway in Transgenic Tobacco”, Plant Molecular Biology, 30:781-793 (1996).
Siemoneit et al., “Human Monoclonal Antibodies for the Immunological Characterization of a Highly Conserved Protein Domain of the Hepatitis C Virus Glycoprotein El,” Clinical and Experimental Immunology 101:278-283 (1995).
Takeda et al., “GPI-Anchor Biosynthesis,” Trends in Biochemical Sciences, 20(9):367-371 (1995).
Ulivieri et al., “Generation of a Monoclonal Antibody to a Defined Portion of theHelicobacter pyloriVacuolating Cytotoxin by DNA Immunization,” J. Biotech 51:191-194 (1996).
Wang et al., “Induction of Antigen-Specific Cytotoxic T Lymphocytes in Humans by a Malaria DNA Vaccine,” Science 282:476-480 (1998).
Yew et al., “Optimization of Plasmid Vectors for High-Level Expression in Lung Epithelial Cells,” Hum. Gene Ther. 8:575-584 (1997).
Blazer et al., J. Immunol. 157:3250-3259 (1996).
NCBI record Accession No. Q69091 (2008).
Lee Helen
Novartis Vaccines and Diagnostics SRL
Ouspenski Ilia
Robins Roberta
LandOfFree
Dimeric proteins for immunization does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dimeric proteins for immunization, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dimeric proteins for immunization will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2718766